KRAKEN (Knowledge Research & Analysis Kit for Evidence Networks) addresses this gap by integrating existing graphs with specialized sources such as RefMet, LIPID MAPS, NIH Common Data Elements, Polygenic Score Catalog, and derived wellness measures including biological age and biological BMI.
Abstract
Existing general-purpose biomedical knowledge graphs tend to focus on disease mechanisms and drug repurposing, leaving multiomic and wellness-relevant content underrepresented. KRAKEN (Knowledge Research & Analysis Kit for Evidence Networks) addresses this gap by integrating existing graphs (including Translator KG Open, RTX-KG2, and ROBOKOP) with specialized sources such as RefMet, LIPID MAPS, NIH Common Data Elements, Polygenic Score Catalog, and derived wellness measures including biological age and biological BMI. The resulting graph spans ∼15M nodes and ∼113M edges across 62 entity types. KRAKEN adopts the Biolink Model as its semantic layer, ensuring compatibility with standardized resources emerging from the NIH NCATS Biomedical Data Translator program. A lightweight, modular build system rebuilds the full graph (including entity resolution), with peak memory consumption <48 GB, and supports flexible inclusion or exclusion of sources, allowing the user to scope the graph to a domain of interest. Built-in analytical tools include multi-hop reasoning, subgraph extraction, text, vector and hybrid entity search, and enrichment analyses, all accessible through an interactive web interface, a REST API, and a Model Context Protocol server, the last enabling direct consumption by agentic and LLM-based systems. KRAKEN is freely available at https://app.krakenkg.com. GRAPHICAL ABSTRACT
Identifying causal connections between existing drugs and mechanistic profiles of diseases is a foundational step for effective drug repurposing. Although knowledge graphs (KGs) are highly suited for consolidating biomedical databases and tracking these connections, a single biomedical KG is constrained by its ingestio...
Piotr Kaniewski, E. K. Carter, Daniel J. Rhodes et al.· bioRxiv· 0 citations
By unifying fragmented research and enabling robust data exploration, UKB-KG emerges as a powerful tool for advancing biomedical research and driving innovative healthcare applications.
Z. Wang, J. Wang, Y. Shen et al.· medRxiv· 0 citations
Initial experiments on heart-failure-focused clinical question answering show that CGX improves evidence retrieval quality and perceived answer reliability over conventional retrieval methods, while reducing total graph construction time by 69.7% under the same input corpus and hardware setting.
Dat T. Nguyen, Ngoc-Anh Thi Le, Binh T. D. Trinh et al.· Journal of Biomedical Inform...· 0 citations
PrimeKG-Plus restores the temporal relevance of PrimeKG, providing an updated resource for drug repurposing, rare-disease research, and downstream machine-learning applications.
Trinh-Trung-Duong Nguyen, T. Nguyen-Phuong, Quy-Hoai Nguyen et al.· bioRxiv· 0 citations
To support clinically meaningful implementation, in future work, rigorous real-world evaluation should be prioritized and challenges related to data quality, interoperability, and model interpretability should be addressed.
Zi-Ting Xu, Chun-Hao Dai, Hao-Yuan Li et al.· BMC Medical Informatics and...· 0 citations
This work introduces MolBioKG, a two-layer system that grounds unseen molecules in biomedical evidence via multi-resolution structural anchoring and outperforms strong baselines across in-graph link recovery, complex multi-hop reasoning, and out-of-graph generalization.
Yiming Zhang, Hikaru Shindo, Shuan Chen et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.